An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared on LinkedIn:
”Today, at the Late-Breaking Abstract Session at the 67th American Society of Hematology Annual Meeting and Exposition, we shared positive results from a Phase III trial in adults with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.
With a course of four once-monthly doses, our investigational therapy studied in this trial offers a promising alternative to chronic treatment.
ITP is a rare autoimmune condition where the immune system mistakenly destroys platelets, leading to prolonged bleeding, easy bruising and chronic fatigue.
This potential treatment is designed to target B cells, a key driver in ITP and other autoimmune diseases, through a dual mechanism of action.
Today’s results represent an important step forward in ITP and add to the growing body of evidence for this therapy, which is currently being studied across multiple B cell-driven conditions.
Thank you to all the patients, investigators, and teams involved in this research.”
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring